Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis
Primary Purpose
Chronic Sinusitis
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Steroid-Eluting Sinexus Intranasal Splint
Sponsored by
About this trial
This is an interventional supportive care trial for Chronic Sinusitis focused on measuring Patients diagnosed with Chronic Sinusitis undergoing functional endoscopic surgery (FESS)
Eligibility Criteria
Inclusion Criteria:
- Patient is 18 years of age or older
- Patient has a diagnosis of chronic sinusitis
- Patient has a clinical indication for and has consented to FESS
- Patient CT scan confirms CS diagnosis within 6 months of procedure
- CT sacn confirms presence of disease in ethmoid sinus(es)
- Planned FESS includes unilateral or bilateral total ethmoidectomy
Exclusion Criteria:
- Immune deficiency (IGG subclass deficiency or IGA deficiency)
- Oral-steroid dependent COPD, asthma or other condition
- Clinical evidence of acute bacterial sinusitis
- History or diagnosis of glaucoma or ocular hypertension
- Clinical evidence or suspicion of invasive fungal sinusitis
- Evidence of disease or condition expected to compromise survival or ability to complete follow-up
- Known history of allergy or intolerance to corticosteroids
- History of insulin dependent diabetes
Sites / Locations
- Central California Ear, Nose Thraot
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sinexus Intranasal Splint
Arm Description
Patient receives a drug-coated intranasal splint
Outcomes
Primary Outcome Measures
Safety as Determined by the Frequency of Serious Adverse Local Tissue Response (SALT)
Device Placement Success Rate
A proportion where the numerator is the number of successful device placements and denominator is the number of attempted sinuses.
Secondary Outcome Measures
Assessment of Changes From Baseline in Intra-ocular Pressure and Lens Opacities
Ocular safety was characterized by assessing the frequency and severity of changes from baseline in intra-ocular pressure and lens opacities. No specific pass/fail criteria we specified.
Number of Sinuses With Significant Post-operative Adhesion Formation
Adhesions were graded on a 5 point categorical scale with grades 3 and 4 considered clinically significant. 0=none, 1=small/non-obstructing, 2=obstructing/easily separated, 3=dense/obstructing/difficult to separate, and 4=severe/complete adhesion to lateral nasal wall.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00912405
Brief Title
Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis
Official Title
A Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
June 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intersect ENT
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study allows continued access to the Sinexus Intranasal Splint while a marketing application is being prepared. This study will generate additional performance, reimbursement and safety data for the steroid-eluting Sinexus Intranasal Splint when used following Functional Endoscopic Sinus Surgery (FESS) in patients with chronic sinusitis (CS).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Sinusitis
Keywords
Patients diagnosed with Chronic Sinusitis undergoing functional endoscopic surgery (FESS)
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sinexus Intranasal Splint
Arm Type
Experimental
Arm Description
Patient receives a drug-coated intranasal splint
Intervention Type
Device
Intervention Name(s)
Steroid-Eluting Sinexus Intranasal Splint
Intervention Description
Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
Primary Outcome Measure Information:
Title
Safety as Determined by the Frequency of Serious Adverse Local Tissue Response (SALT)
Time Frame
30 days
Title
Device Placement Success Rate
Description
A proportion where the numerator is the number of successful device placements and denominator is the number of attempted sinuses.
Time Frame
At the time of procedure
Secondary Outcome Measure Information:
Title
Assessment of Changes From Baseline in Intra-ocular Pressure and Lens Opacities
Description
Ocular safety was characterized by assessing the frequency and severity of changes from baseline in intra-ocular pressure and lens opacities. No specific pass/fail criteria we specified.
Time Frame
Baseline and 30 days
Title
Number of Sinuses With Significant Post-operative Adhesion Formation
Description
Adhesions were graded on a 5 point categorical scale with grades 3 and 4 considered clinically significant. 0=none, 1=small/non-obstructing, 2=obstructing/easily separated, 3=dense/obstructing/difficult to separate, and 4=severe/complete adhesion to lateral nasal wall.
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is 18 years of age or older
Patient has a diagnosis of chronic sinusitis
Patient has a clinical indication for and has consented to FESS
Patient CT scan confirms CS diagnosis within 6 months of procedure
CT sacn confirms presence of disease in ethmoid sinus(es)
Planned FESS includes unilateral or bilateral total ethmoidectomy
Exclusion Criteria:
Immune deficiency (IGG subclass deficiency or IGA deficiency)
Oral-steroid dependent COPD, asthma or other condition
Clinical evidence of acute bacterial sinusitis
History or diagnosis of glaucoma or ocular hypertension
Clinical evidence or suspicion of invasive fungal sinusitis
Evidence of disease or condition expected to compromise survival or ability to complete follow-up
Known history of allergy or intolerance to corticosteroids
History of insulin dependent diabetes
Facility Information:
Facility Name
Central California Ear, Nose Thraot
City
Fresno
State/Province
California
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis
We'll reach out to this number within 24 hrs